Immunotherapy Treatment Patterns and Outcomes Among ALK-Positive Patients With Non–Small-Cell Lung Cancer

Mohammad Jahanzeb; Huamao M. Lin; Xiaoyun Pan; Yu Yin; Pia Baumann; Corey J. Langer

doi:10.1016/j.cllc.2020.08.003

Immunotherapy Treatment Patterns and Outcomes Among ALK-Positive Patients With Non–Small-Cell Lung Cancer

Mohammad Jahanzeb, Huamao M. Lin, Xiaoyun Pan, Yu Yin, Pia Baumann, Corey J. Langer

Research output: Contribution to journal › Article › peer-review

Abstract

The efficacy of immune checkpoint inhibitors (ICI) in ALK-positive non–small-cell lung cancer (NSCLC) is inconclusive as a result of limited data. We conducted a real-world analysis in 83 patients with ALK⁺ advanced NSCLC treated with ICI. The median real-world progression-free survival was 2.34 months from initiation of ICI therapy. The real-world effectiveness of ICI in ALK⁺ NSCLC patients was limited.

Original language	English (US)
Pages (from-to)	49-57
Number of pages	9
Journal	Clinical Lung Cancer
Volume	22
Issue number	1
DOIs	https://doi.org/10.1016/j.cllc.2020.08.003
State	Published - Jan 2021
Externally published	Yes

Keywords

Cancer genomics
Immune checkpoint inhibitor
Next-generation sequencing
Resistance
Targeted therapy

ASJC Scopus subject areas

Oncology
Pulmonary and Respiratory Medicine
Cancer Research

Access to Document

10.1016/j.cllc.2020.08.003

Fingerprint Dive into the research topics of 'Immunotherapy Treatment Patterns and Outcomes Among ALK-Positive Patients With Non–Small-Cell Lung Cancer'. Together they form a unique fingerprint.

Cite this

@article{8ed014639b154b7ba79d35e2335ae695,

title = "Immunotherapy Treatment Patterns and Outcomes Among ALK-Positive Patients With Non–Small-Cell Lung Cancer",

abstract = "The efficacy of immune checkpoint inhibitors (ICI) in ALK-positive non–small-cell lung cancer (NSCLC) is inconclusive as a result of limited data. We conducted a real-world analysis in 83 patients with ALK+ advanced NSCLC treated with ICI. The median real-world progression-free survival was 2.34 months from initiation of ICI therapy. The real-world effectiveness of ICI in ALK+ NSCLC patients was limited.",

keywords = "Cancer genomics, Immune checkpoint inhibitor, Next-generation sequencing, Resistance, Targeted therapy",

author = "Mohammad Jahanzeb and Lin, {Huamao M.} and Xiaoyun Pan and Yu Yin and Pia Baumann and Langer, {Corey J.}",

note = "Funding Information: Funded by Millennium Pharmaceuticals Inc , a wholly owned subsidiary of Takeda Pharmaceutical Company Limited . Medical writing support and editorial assitance was provided by Xcenda LLC, and funded by Millenium Pharmaceuticals Inc. Publisher Copyright: {\textcopyright} 2020 The Authors Copyright: Copyright 2021 Elsevier B.V., All rights reserved.",

year = "2021",

month = jan,

doi = "10.1016/j.cllc.2020.08.003",

language = "English (US)",

volume = "22",

pages = "49--57",

journal = "Clinical Lung Cancer",

issn = "1525-7304",

publisher = "Elsevier",

number = "1",

}

TY - JOUR

T1 - Immunotherapy Treatment Patterns and Outcomes Among ALK-Positive Patients With Non–Small-Cell Lung Cancer

AU - Jahanzeb, Mohammad

AU - Lin, Huamao M.

AU - Pan, Xiaoyun

AU - Yin, Yu

AU - Baumann, Pia

AU - Langer, Corey J.

N1 - Funding Information: Funded by Millennium Pharmaceuticals Inc , a wholly owned subsidiary of Takeda Pharmaceutical Company Limited . Medical writing support and editorial assitance was provided by Xcenda LLC, and funded by Millenium Pharmaceuticals Inc. Publisher Copyright: © 2020 The Authors Copyright: Copyright 2021 Elsevier B.V., All rights reserved.

PY - 2021/1

Y1 - 2021/1

N2 - The efficacy of immune checkpoint inhibitors (ICI) in ALK-positive non–small-cell lung cancer (NSCLC) is inconclusive as a result of limited data. We conducted a real-world analysis in 83 patients with ALK+ advanced NSCLC treated with ICI. The median real-world progression-free survival was 2.34 months from initiation of ICI therapy. The real-world effectiveness of ICI in ALK+ NSCLC patients was limited.

AB - The efficacy of immune checkpoint inhibitors (ICI) in ALK-positive non–small-cell lung cancer (NSCLC) is inconclusive as a result of limited data. We conducted a real-world analysis in 83 patients with ALK+ advanced NSCLC treated with ICI. The median real-world progression-free survival was 2.34 months from initiation of ICI therapy. The real-world effectiveness of ICI in ALK+ NSCLC patients was limited.

KW - Cancer genomics

KW - Immune checkpoint inhibitor

KW - Next-generation sequencing

KW - Resistance

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85096861075&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85096861075&partnerID=8YFLogxK

U2 - 10.1016/j.cllc.2020.08.003

DO - 10.1016/j.cllc.2020.08.003

M3 - Article

C2 - 33250347

AN - SCOPUS:85096861075

VL - 22

SP - 49

EP - 57

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

SN - 1525-7304

IS - 1

ER -